Early Access — free while we kick the tires
EdgarHawk

Wulf John William

Director

Director
2 filings analyzed · 1 company · Latest 2026-01-30

Companies

Company Buys Sells Direction
agilon health, inc. AGL 2 0 Net buying

Activity

January 2026
2026-01-30 agilon health, inc. AGL
high
Buy
81,000 shares
$50,941
Significance 6/10

Director Wulf John William bought 81,000 shares of AGL at $0.63 on 2025-11-12, increasing holdings by 28.4% to 365.9K shares.

Director Wulf John William purchased 81,000 shares at $0.63 on 2025-11-12, a substantial addition that increased his holdings by 28.4% from 284.9K to 365.9K shares. This buy occurred when the stock traded near its 52-week low ($12.84–$142.00 range, currently $20.80), representing an -85.4% decline from the 52-week high. His prior purchase at this ticker on 2024-12-05 achieved a 90-day return of +3957.8%, demonstrating successful timing on that occasion. The company reported latest-quarter revenue of $1.4B with annual growth of +40.4%, but remains unprofitable with net income of $-110.2M, so the fundamental picture is mixed growth and continued losses.

December 2024
2024-12-11 agilon health, inc. AGL
high
Buy
45,000 shares
$98,145
Significance 6/10

Director Wulf John William bought 45,000 AGL shares at $2.18; cluster of 3 insider buys in 14 days amid -85.3% decline from 52-week high.

Director Wulf John William purchased 45,000 shares at $2.18 on 2024-12-05, increasing his holdings from 161.1K to 206.1K shares (+27.9%). The transaction occurs in a cluster context—2 other insiders also bought within the past 14 days, establishing a multi-insider buying pattern at a compressed valuation. AGL trades at $49.75 currently, representing a -85.3% decline from its 52-week high of $339.25 and a -7.9% drop over the past 30 days. The company generated $1.5B in quarterly revenue with +59.4% annual growth but is unprofitable, posting $-117.6M in net income for the most recent full fiscal year. The coincident buying by three directors at depressed price levels relative to recent highs warrants attention to understand whether this reflects asymmetric information regarding operational recovery or strategic repositioning.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access